Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

Exclusion Criteria

• •Who has hyper sensitivity reaction about other drugs, ingredients, components of investigator product or compound of benzimidazole.
• •Who has ERD.
• •Who get a diagnosis as a IBS within the last 3 months.
• •Who have taken drugs about reflux esophagitis (H₂-receptor inhibitor (H2RA) Prostaglandin(PG), Antacid, Prokinetic acid etc.) above 2 times as an usual dose. (\* refer to the Concomitant medication in text.)
• •Who havbe taken gastric acid secretion inhibitors including PPIs within 2 weeks before the endoscopy.
• •Who has been experienced the disease affecting the esophagus(Eosinophilic esophagitis, esophageal varices, cirrhosis, Virus or Fungal infection, Esophageal stricture, primary esophageal motility disorder and gastrointestinal bleeding). Or who has a history of radio therapeutics, freeze treatment about the esophagus.
• •Who has the gastric or duodenal ulcer, Zollinger-Ellison and other acid hypersecretory condition been experienced.
• •Who has hyper-sensitivity, reaction about PPIs (ex. Lansoprazole, omeprazole, rabeprazole, pantoprazole or esomeprazole).
• •Who has gotten a diagnosis as a cancer within 5 years before participated in this clinical trail (expect the basal cell on the skin), peptic ulcer or benign tumor.